In a recent study, patients undergoing cancer treatment who received a COVID-19 mRNA vaccine produced antibodies at a slower rate than people without cancer, but most were seropositive after the second dose. The results, published in JAMA Oncology, reinforce the recommendation to prioritize patients with cancer for vaccination against SARS-CoV-2.
The study, conducted in Israel, involved 232 patients with cancer with an average age of 66 years and a healthy, age–matched control group of 261 health care workers, all of whom received Pfizer-BioNTech’s SARS-CoV-2 vaccine.
Slomski A. Most Fully Vaccinated Patients With Cancer Have SARS-CoV-2 Antibodies. JAMA. 2021;326(9):800. doi:10.1001/jama.2021.14707
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: